Search Results for "Arthritis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Arthritis. Results 21 to 30 of 36 total matches.

Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
for treatment of plaque psoriasis and psoriatic arthritis.1 STANDARD TREATMENT ― The tumor necrosis factor ...
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment of plaque psoriasis and psoriatic arthritis.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):205-7 |  Show IntroductionHide Introduction

Rilonacept (Arcalyst) for Recurrent Pericarditis

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
arthritis, has been used off-label for years for treatment of recurrent pericarditis. THE DISORDER ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1) antagonist that has been available for years for treatment of cryopyrin-associated periodic syndromes, has now been approved by the FDA for treatment of recurrent pericarditis and prevention of further recurrences in patients ≥12 years old. It is the first drug to be approved in the US for this indication. Anakinra (Kineret), an IL-1 receptor antagonist FDA-approved for treatment of rheumatoid arthritis, has been used off-label for years for treatment of recurrent pericarditis.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):143-4 |  Show IntroductionHide Introduction

Bimekizumab (Bimzelx) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024  (Issue 1694)
arthritis. Arthritis Rheumatol 2019; 71:5. 2. A Menter et al. Joint American Academy of Dermatology ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx – UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy. Bimekizumab is the first IL-17A/17F antagonist to be approved in the US. It was approved in the European Union for the same indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3   doi:10.58347/tml.2024.1694b |  Show IntroductionHide Introduction

Belimumab (Benlysta) for Lupus Nephritis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021  (Issue 1634)
of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64:797. 5. M Dall'Era et al. Comparison ...
The B-lymphocyte stimulator (BLyS)-specific inhibitor belimumab (Benlysta – GSK), which was approved earlier for treatment of active, autoantibody-positive, nonrenal, systemic lupus erythematosus (SLE), has now been approved for use in addition to standard therapy for treatment of active lupus nephritis in adults. Belimumab is the first drug to be approved in the US for treatment of both SLE and lupus nephritis.
Med Lett Drugs Ther. 2021 Sep 23;63(1634):e3-4 |  Show IntroductionHide Introduction

An EUA for Anakinra (Kineret) for COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis ...
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra (Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are...
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e203-4 |  Show IntroductionHide Introduction

Voclosporin (Lupkynis) for Lupus Nephritis

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
. Arthritis Care Res (Hoboken) 2012; 64:797. 2. M Dall’Era et al. Comparison of standard of care treatment ...
Voclosporin (Lupkynis – Aurinia), an oral calcineurin inhibitor, has been approved by the FDA for use in combination with the antimetabolite immunosuppressant mycophenolate mofetil (Cellcept, and generics) and a corticosteroid for treatment of adults with active lupus nephritis. It is the first calcineurin inhibitor to be approved in the US for this indication. Tacrolimus (Prograf, and others) and cyclosporine (Neoral, and others), the other available systemic calcineurin inhibitors, are approved for prophylaxis of organ rejection in transplant patients.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):134-6 |  Show IntroductionHide Introduction

Ritlecitinib (Litfulo) for Severe Alopecia Areata

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386:316. 
 12. Inhibitors and inducers of CYP enzymes ...
The FDA has approved ritlecitinib (Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment of severe alopecia areata; baricitinib (Olumiant), a JAK inhibitor, is approved only for use in adults.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):185-6   doi:10.58347/tml.2023.1690a |  Show IntroductionHide Introduction

Risankizumab (Skyrizi) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
and psoriatic arthritis.1 STANDARD TREATMENT — An aminosalicylate such as mesalamine (Lialda, and others ...
The injectable interleukin (IL)-23 antagonist risankizumab-rzza (Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is also approved for treatment of plaque psoriasis and psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4   doi:10.58347/tml.2024.1715d |  Show IntroductionHide Introduction

Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025  (Issue 1730)
earlier for treatment of ulcerative colitis (UC), plaque psoriasis, and psoriatic arthritis.1 The IL-23 ...
The injectable interleukin (IL)-23 antagonist guselkumab (Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults; it was approved earlier for treatment of ulcerative colitis (UC), plaque psoriasis, and psoriatic arthritis. The IL-23 antagonists risankizumab (Skyrizi) and mirikizumab (Omvoh) and the IL-12/23 antagonist ustekinumab (Stelara, and biosimilars) are also approved for treatment of CD.
Med Lett Drugs Ther. 2025 Jun 9;67(1730):92-4   doi:10.58347/tml.2025.1730c |  Show IntroductionHide Introduction

Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
, vomiting, hemorrhage, diarrhea, abdominal pain, arthralgia, and arthritis. Hypoadrenalism, hypothyroidism ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for once-weekly subcutaneous (SC) treatment of growth failure due to inadequate secretion of endogenous growth hormone in children ≥1 year old who weigh ≥11.5 kg. It is the first once-weekly rhGH product to be approved in the US; other available rhGH formulations are administered more frequently.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):20-2 |  Show IntroductionHide Introduction